Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning these changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Carraway, Hetty E., Malkaram, Sridhar A., Cen, Yana, Shatnawi, Aymen, Fan, Jun, Ali, Hamdy E. A., Abd Elmageed, Zakaria Y., Buttolph, Thomm, Denvir, James, Primerano, Donald A., Fandy, Tamer E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316973/
https://www.ncbi.nlm.nih.gov/pubmed/32587297
http://dx.doi.org/10.1038/s41598-020-67170-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316973/
https://www.ncbi.nlm.nih.gov/pubmed/32587297
http://dx.doi.org/10.1038/s41598-020-67170-8

Ejemplares similares